SCHEMBL27639783

SCHEMBL27639783

COc1ccc(C(CN)(C(N)=O)c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 10/20 0.51
▸ KCNH2 Q12809 2/20 0.51
▸ CES2 O00748 1/20 0.45
▸ CES1 P23141 1/20 0.45
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CHRM2 P08172 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ CA1 P00915 2/20 0.44
▸ CA2 P00918 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ CTDSP1 Q9GZU7 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ PARP10 Q53GL7 1/20 0.43
▸ PARP2 Q9UGN5 1/20 0.43
▸ PARP4 Q9UKK3 1/20 0.43
▸ MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27639681 0.87 KIF11 (0.50) KIF11KCNH2CES2CES1NPC1
SCHEMBL30241803 0.79 KIF11 (0.53) KIF11KCNH2CES2CES1NPC1
SCHEMBL27639725 0.79 KCNN4 (0.64) KIF11KCNH2LMNACHRM2CYP2D6
SCHEMBL2319756 0.79 KMT2A (0.54) KIF11KCNH2CES2CES1NPC1
SCHEMBL5060670 0.78 KIF11 (0.50) KIF11KCNH2CES2CES1NPC1
SCHEMBL17964412 0.76 KIF11 (0.70) KIF11KCNH2LMNA
SCHEMBL28305536 0.76 KIF11 (0.49) KIF11KCNH2CES2CES1NPC1
SCHEMBL17833432 0.75 KCNN4 (0.54) KIF11KCNH2CES2CES1NPC1
SCHEMBL29882115 0.75 CHRM3 (0.50) KCNH2CES1LMNACHRM2CYP2D6
SCHEMBL31404235 0.74 KIF11 (0.50) KIF11KCNH2CES2CES1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101790374-A Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted LUNDBECK & CO AS H 2010-07-28 — — CN claimed
CN-101378742-B Use of KCNQ-openers for the preparation of a pharmaceutical composition for the treatment of schizophrenia LUNDBECK & CO AS H 2013-07-10 — — CN disclosed
CN-101790374-A Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted LUNDBECK & CO AS H 2010-07-28 — — CN disclosed
CN-1761464-A Substituted p-diaminobenzene derivatives LUNDBECK & CO AS H (DK) 2006-04-19 — — CN disclosed
Send feedback